Clinical Application of Serum Tumor Abnormal Protein from Patients with Gastric Cancer

Background: To verify whether serum tumor abnormal protein (TAP) would correlate with the responsivenessof palliative chemotherapy in patients with advanced gastric cancer, and the variation of conventional serumtumor markers e.g., carcinoembryonic antigen (CEA), antigen 125 (CA125),carbohydrate antigen19-9 (CA19-9) ofadjuvant chemotherapy in patients with early gastric cancer. Materials and
Methods: Patients with histologicallyconfirmed gastric cancer and treated with chemotherapy were enrolled into this study. TAP values of thesepatients were determined by detecting abnormal sugar chain glycoprotein in serum, combined with the area ofagglomerated particles. For patients with advanced gastric cancer, responsiveness of palliative chemotherapywas compared with variation of TAP and the relation between variation of TAP and tumor markers in patientswith early gastric cancer was analyzed.
Results: Totally 82 gastric cancer patients were enrolled into this study.The value of TAP is more closely related to responsiveness of palliative chemotherapy for patients with advancedgastric cancer. The correlation between TAP and responsiveness to palliative chemotherapy is stronger thanthe correlation between several conventional serum tumor markers (CEA, CA125 and CA199) .The variationof TAP was also positively correlated with the trend of CA125 in adjuvant chemotherapy.
Conclusions: TAP issensitive in monitoring the responsiveness to palliative chemotherapy in patients with advanced gastric cancer.But this result should be confirmed by randomized clinical trials for patients with gastric cancer.